Researchers have developed a personalized blood test that may offer a faster, less invasive way to track high-grade glioma progression.

A new study reveals blood tests can predict melanoma recurrence by detecting circulating tumor DNA. Research shows 80% of ...

Authorities seized evidence that tested positive for the presence of human blood from the home where Jeremy Stanton fled ...

A new study finds that fragments of tumor DNA in a patient's bloodstream could show that they are at high risk of a melanoma ...

Catching cancer early using a blood test—called a “liquid biopsy”—has long been a goal of cancer research. Such tests would ...

Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments ...

Using the Ultima Genomics’ (CA, USA) lower-cost WGS platform and the known mutational patterns in patient tumors as a guide, ...

Stanford Medicine researchers have created a liquid biopsy test capable of detecting cancers, molecular mechanisms of ...

Mayo Clinic researchers have identified a potential new way to monitor the progression of high-grade gliomas, one of the most aggressive types of brain cancer. Their feasibility study suggests that a ...

Detecting cell-free messenger RNA means the blood test is capable of monitoring conditions that do not involve genetic mutations that are the basis of most DNA-based tests, such as certain causes ...

ARUP Laboratories has introduced a blood test for phosphorylated tau 217 (pTau 217) to aid in diagnosing the pathology of ...